EP4424303A1 — Lenvatinib composition with improved bioavailability
Assigned to Zhejiang Qizheng Pharmaceutical Co ltd · Expires 2024-09-04 · 2y expired
What this patent protects
The invention is directed to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib salt and potassium carbonates, in particular potassium hydrogen carbonate, wherein the weight ratio of Lenvatinib salt to potassium carbonates is selected within a …
USPTO Abstract
The invention is directed to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib salt and potassium carbonates, in particular potassium hydrogen carbonate, wherein the weight ratio of Lenvatinib salt to potassium carbonates is selected within a range from 1 : 0.3 to 1 : 3.0.
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.